Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01964430 · ClinicalTrials.gov registry record · Phase 3
Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)
A Phase 3 study of Neoplasms and Pancreatic Neoplasms, sponsored by Celgene.
- Completed
- Registry status
- Phase 3
- Development phase
- 866
- Enrollment target
- 20
- Study locations
NCT01964430 is a Phase 3 study of Neoplasms and Pancreatic Neoplasms that has completed, run by Celgene. The registered enrollment target is 866 participants, below the 1,616-participant average among 158 other Neoplasms trials with a reported enrollment target (46% lower). The trial reports 20 study locations across 5 states.
The verdict
NCT01964430, a Phase 3 study of Neoplasms and Pancreatic Neoplasms, has completed, sponsored by Celgene.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 866 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare whether there is a delay or prevention of recurrence or death in participants with surgically removed pancreatic cancer who then take nab-Paclitaxel in combination with gemcitabine compared to those who take gemcitabine alone.
Conditions Studied
Interventions
- DRUG Gemcitabine
- DRUG nab-Paclitaxel
Study Locations (20)
California
- UCSD Moores Cancer Center - La Jolla
- University of Southern California - Los Angeles
- Local Institution - 044 - Sacramento
- UC Davis Cancer Center - Sacramento
- Local Institution - 001 - San Francisco
- University of California, San Francisco Cutaneous Oncology and Melanoma Center - San Francisco
- University of California Los Angeles - Santa Monica
Florida
- Local Institution - 022 - Boca Raton
- Lynn Cancer Institute - Boca Raton
- Florida Cancer Institute Cancer Spec - Fort Myers
- Local Institution - 031 - Fort Myers
- Gainesville Heme Oncology Associates - Gainesville
- Local Institution - 011 - Gainesville
- University of Florida - Gainesville
Colorado
- University of Colorado Cancer Center - Aurora
- Local Institution - 059 - Denver
- Rocky Mountain Cancer Centers, LLP [Denver-Midtown] - Denver
Arizona
- Local Institution - 043 - Scottsdale
- Mayo Clinic - Arizona - Scottsdale
Connecticut
- Yale Cancer Center - New Haven
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 866 participants |
| Start Date | 2014-03-28 |
| Est. Completion | 2022-06-30 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01964430
The ClinicalTrials.gov registry entry for NCT01964430 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 866 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,616-participant average among 158 other Neoplasms trials with a reported enrollment target (46% lower). The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Neoplasms appearing as the primary indexed condition, and to 2 interventions - of which Gemcitabine is the first listed.
NCT01964430 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT01964430 about?
NCT01964430 is a clinical study titled "Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study)". The purpose of this study is to compare whether there is a delay or prevention of recurrence or death in participants with surgically removed pancreatic cancer who then take nab-Paclitaxel in combination with gemcitabine compared to those who take gemcitabine alone.
What is the current status of trial NCT01964430?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 866 participants. The study started on 2014-03-28. Estimated completion is 2022-06-30.
What conditions does trial NCT01964430 study?
This clinical trial studies the following conditions: Neoplasms, Pancreatic Neoplasms, Neoplasms by Site, Endocrine System Diseases, Pancreatic Diseases.
What interventions are being tested in trial NCT01964430?
The interventions under investigation include: Gemcitabine (DRUG), nab-Paclitaxel (DRUG).
Who is sponsoring clinical trial NCT01964430?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01964430 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neoplasms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation
ACTIVE NOT RECRUITING · Phase 3
-
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
ACTIVE NOT RECRUITING · Phase 3
-
XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
COMPLETED · Phase 3
-
Multimodal Intervention for Cachexia in Advanced Cancer Patients Undergoing Chemotherapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.